Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kaatz

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
The British Journal of Dermatology|September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT studyR Dummer, A Guminksi, R Gutzmer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2017
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT studyJ T Lear, M R Migden, K D Lewis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|September 12, 2013
[Phlebology in German departments of dermatology. An analysis on behalf of the German Society of Phlebology]S Reich-Schupke, J Alm, P Altmeyer, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
The British Journal of Dermatology|September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT studyR Dummer, A Guminksi, R Gutzmer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2017
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT studyJ T Lear, M R Migden, K D Lewis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|September 12, 2013
[Phlebology in German departments of dermatology. An analysis on behalf of the German Society of Phlebology]S Reich-Schupke, J Alm, P Altmeyer, et al.
Pageof 6